The Rise of Telemedicine: Embracing a New Normalcy

By: Saniel Chandrawat

Senior Investment Analyst – Healthcare, Energy, Utilities

The pandemic has accelerated trends and generated new investment opportunities. Telemedicine is a paradigm.

Telemedicine is the use of modern telecommunications technology that enables a patient to reach medical consultation through an app using artificial intelligence. The process involves a symptom brief then in real-time exchanging the information with a live doctor where diagnosis and recommendation are approved with professional feedback. This new technology integrates with a one-stop-shop where the patient’s prescription is registered, and medication is then delivered to the patient’s door. All of this is achievable within the comfort of one’s home.

Overcoming Healthcare System Challenges

Over the past decade, the healthcare systems in Asian countries have faced fundamental structural issues, including demand-supply imbalances of medical resources, low compensation, and lack of job satisfaction for many medical practitioners in comparison with other major economies.

The increasing popularity of online medical services platforms could remediate the situation of our healthcare system. Telemedicine could:

Divert less severely ill patients away from tier-one hospitals where resources are tight, by applying a multi-tiered medical system.
Save public insurance expenses and ease the problem of medication overload.
Provide other sources of income for medical practitioners.

Digital Healthcare Transformation

Online medical consultation platforms have attracted more users during the COVID-19 crisis. We believe this is a perfect storm to shift offline consumer behavior to an online platform. To facilitate physical isolation and reduce cross-infection, the Chinese government has further supported its adoption, encouraging the utilization of online healthcare services.

We have seen unprecedented demands for telehealth in the wake of the rise of online solutions in healthcare services. For example, China’s largest healthcare platform, Ping An Good Doctor, from late-Jan 2020 to early-Feb 2020, witnessed:

1.11 billion accumulated visits on the platform*
10 times the number of accumulated new registered users*
9 times the daily consultations by newly registered users on App*

Chinese Government Support

Earlier in April 2020, the NDRC (National Development and Reform Commission), in conjunction with the Cyberspace Administration, issued a document proposing the development of new digital industries “Internet Plus Healthcare.”

The promotion adopts medical insurance services during the prevention and control of COVID-19, supporting the reimbursement of qualified online medical consultations services of common diseases, chronic diseases, and the e-prescription filings for re-visit patients. The guidance urges cooperation between the Provincial Healthcare Security Administration and internet hospitals on the direct online settlement by medical insurance.

Some pilot cities, such as Yinchuan, Guizhou, and Inner Mongolia, have already started promoting internet-related treatments alongside price guidance. More provinces are now joining the bandwagon. The reimbursement rate for online diagnosis lies in the range of RMB6-50 per consultation.

To further promote telehealth, Fuzhou’s Municipal Health Commission signed a new agreement with Ping An Good Doctor in October 2019, establishing a centralized internet hospital platform. It was made compulsory for all bricks-and-mortar hospitals in Fuzhou to join.

With an accelerated application on country and city level, we have seen an increase in the usage of online hospitals over the past few months.

In addition to China, digital health platforms in other Asian countries such as Indonesia and India are reporting a surge in activities, too.

Telemedicine Ramps Up in Indonesia

The three most significant digital health platforms in Indonesia, including Alodokter, Halodoc, and GrabHealth (a joint venture between Singapore-based ride-hailer Grab and a Chinese healthcare company), have seen their usage skyrocket in March 2020. Alodokter clocked 32 million website visits in March and over 500,000 free coronavirus consultations since Indonesia’s first confirmed case on March 2, according to Alodokter Chief Executive Nathanael Faibis. In April 2020, Grabhealth said daily consultations had nearly doubled to 10,000.

To fight against COVID-19, Indonesia’s local government and authorities are actively promoting telehealth services. For example, the Indonesian Government COVID-19 task force announced on March 27 that twenty digital health services platforms would be added to its website, supporting the applications of telehealth services. A digital call centre will be established to direct the traffics of requests. On province-level, 49 million residents in West Java could enjoy the digital health care services, registering for COVID-19 testing through the online platform.

India – Telehealth Becomes a Reality

India formally commenced telemedicine recently. The regulatory body NITI Aayog issued Telemedicine Practice Guidelines on March 25, 2020, enabling Registered Medical Practitioners (RMPs) to provide healthcare remotely.

As the launch is still at an early stage, the regulation only allows registered medical practitioners to provide healthcare remotely via telemedicine. Albeit new technologies such as AI, IoT, data analytic based decision support systems, etc. could support RMPs on patient consultation, diagnosis, or management, the final prescription or counseling has to be directly delivered by the RMP.

The post-COVID New Normal

Even though the business may face challenges in the post-COVID world, they may also bring into being new normalcy. We believe that telemedicine has the potential to be the new norm of the fast-changing medical landscape.

Disclaimer

This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, o¬ffer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated service. The views and information discussed or referred in this document are as of the date of publication. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may di¬ffer materially from those in such statements.
Investment involves risk. Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Fund will generate a return and there may be circumstances where no return is generated or the amount invested is lost. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Fund and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.
Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (HK) Limited (“MAGIHK”) are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.
The document may contain information and material relating to funds that are authorized by the Securities and Futures Commission (“SFC”) in Hong Kong. SFC authorization is not a recommendation or endorsement of a fund nor does it guarantee the commercial merits of a fund or its performance. It does not mean the fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. The document is prepared by Mirae Asset Global Investments (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.
Hong Kong: This material is prepared by Mirae Asset Global Investments (HK) Limited (Mirae HK). Mirae HK is regulated by the SFC (CE reference: ALK083).
Australia: The information contained on this document is provided by Mirae Asset Global Investments (HK) Limited (“MAGIHK”), which is exempt from the requirement to hold an Australian financial services license under the Corporations Act 2001 (Cth) (Corporations Act) pursuant to ASIC Class Order 03/1103 (Class Order) in respect of the financial services it provides to wholesale clients (as defined in the Corporations Act) in Australia. MAGIHK is regulated by the Securities and Futures Commission of Hong Kong under Hong Kong laws, which differ from Australian laws. Pursuant to the Class Order, this document and any information regarding MAGIHK and its products is strictly provided to and intended for Australian wholesale clients only. By accessing this document and any information or content contained in it, you represent that you are a ‘wholesale client’ under the Corporations Act. This document is strictly for information purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. Further, this document should not be regarded by investors as a substitute for independent professional advice or the exercise of their own judgement. The contents of this document is prepared and maintained by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Australian Investments & Securities Commission. No part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGI HK. Copyright 2020. All rights reserved.
United Kingdom: This document does not explain all the risks involved in investing in the Fund and therefore you should ensure that you read the Prospectus and the Key Investor Information Documents (“KIID”) which contain further information including the applicable risk warnings. The taxation position affecting UK investors is outlined in the Prospectus. The Prospectus and KIID for the Fund are available free of charge from http://investments.miraeasset.eu, or from Mirae Asset Global Investments (UK) Ltd., 4th Floor, 4-6 Royal Exchange Buildings, London EC3V 3NL, United Kingdom, telephone +44 (0)20 7715 9900.
This document has been approved for issue in the United Kingdom by Mirae Asset Global Investments (UK) Ltd, a company incorporated in England & Wales with registered number 06044802, and having its registered office at 4th Floor, 4-6 Royal Exchange Buildings, London EC3V 3NL, United Kingdom. Mirae Asset Global Investments (UK) Ltd. is authorised and regulated by the Financial Conduct Authority with firm reference number 467535.